3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
6
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neurofibromatosis 1
7
Neurofibroma, Plexiform
4
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
2
Recurrence
1
Pain
1
Neoplasms
1
Neoplasm Metastasis
1
Muscle Invasive Bladder Cancer
1
Melanoma
1
Gallbladder Neoplasms
1
Astrocytoma
1
Advanced Non Small Cell Lung Cancer
1
Interventions
pembrolizumab
34
Specimen Handling
18
Paclitaxel
16
Magnetic Resonance Spectroscopy
15
Carboplatin
14
Biopsy
14
Nivolumab
13
Ipilimumab
12
Gemcitabine
10
Irinotecan
9
Radiosurgery
8
atezolizumab
7
abemaciclib
7
Radiation
7
Pemetrexed
7
Cisplatin
7
Capecitabine
7
130-nm albumin-bound paclitaxel
7
trastuzumab deruxtecan
6
olaparib
6
durvalumab
6
avelumab
6
Docetaxel
6
osimertinib
5
adagrasib
5
Trastuzumab
5
Fulvestrant
5
Cetuximab
5
Albumin-Bound Paclitaxel
5
palbociclib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasm Metastasis
×
AZD 6244
×
Clear all
NCT01933932
2025-11-19
SELECT-1
AstraZeneca
Phase 3
Active not recruiting
510 enrolled
16 charts